STOCK TITAN

Hydreight Reports 34% Year-Over-Year Q1 Revenue Growth, Improvement in Bottom Line Results, and Delivers Strong Performance Across Verticals

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Hydreight Technologies (HYDTF) reported strong Q1 2025 financial results with 34% year-over-year revenue growth. The company achieved topline revenue of $6.53M and GAAP revenue of $4.54M, up from $3.38M in Q1 2024. Notably, Hydreight reached profitability with GAAP Net Income of $21K, compared to a $309K loss in Q1 2024, and Adjusted EBITDA of $163K. The company saw significant operational growth with a 65% increase in new nurse signups and 48% growth in pharmacy orders. Hydreight completed a strategic financing of $5.4M gross in February and launched new services including Personalized Genetic Testing and Wellness Solution on their VSDHOne Platform. The company maintains a strong cash position of $6.04M and continues to expand its mobile clinical network across 50 US states.
Hydreight Technologies (HYDTF) ha riportato solidi risultati finanziari nel primo trimestre del 2025 con una crescita del fatturato del 34% rispetto all'anno precedente. L'azienda ha raggiunto un fatturato totale di 6,53 milioni di dollari e un fatturato GAAP di 4,54 milioni di dollari, in aumento rispetto ai 3,38 milioni del primo trimestre 2024. In particolare, Hydreight ha raggiunto la redditività con un utile netto GAAP di 21.000 dollari, rispetto a una perdita di 309.000 dollari nel primo trimestre 2024, e un EBITDA rettificato di 163.000 dollari. L'azienda ha registrato una crescita operativa significativa con un aumento del 65% nelle nuove iscrizioni di infermieri e un incremento del 48% negli ordini in farmacia. Hydreight ha completato un finanziamento strategico di 5,4 milioni di dollari lordi a febbraio e ha lanciato nuovi servizi, tra cui il Test Genetico Personalizzato e la Soluzione Benessere sulla loro piattaforma VSDHOne. L'azienda mantiene una solida posizione di liquidità di 6,04 milioni di dollari e continua a espandere la sua rete clinica mobile in tutti i 50 stati degli Stati Uniti.
Hydreight Technologies (HYDTF) reportó sólidos resultados financieros en el primer trimestre de 2025 con un crecimiento de ingresos interanual del 34%. La compañía alcanzó ingresos totales de 6.53 millones de dólares y ingresos GAAP de 4.54 millones de dólares, frente a 3.38 millones en el primer trimestre de 2024. Destaca que Hydreight logró rentabilidad con un ingreso neto GAAP de 21 mil dólares, comparado con una pérdida de 309 mil dólares en el primer trimestre de 2024, y un EBITDA ajustado de 163 mil dólares. La empresa experimentó un crecimiento operativo significativo con un aumento del 65% en nuevas inscripciones de enfermeros y un crecimiento del 48% en pedidos de farmacia. Hydreight completó una financiación estratégica por 5.4 millones de dólares brutos en febrero y lanzó nuevos servicios, incluyendo Pruebas Genéticas Personalizadas y Soluciones de Bienestar en su plataforma VSDHOne. La compañía mantiene una sólida posición de efectivo de 6.04 millones de dólares y continúa expandiendo su red clínica móvil en los 50 estados de EE.UU.
Hydreight Technologies(HYDTF)는 2025년 1분기에 전년 대비 34% 매출 성장으로 강력한 재무 실적을 보고했습니다. 회사는 653만 달러의 총 매출과 454만 달러의 GAAP 매출을 기록했으며, 이는 2024년 1분기 338만 달러에서 증가한 수치입니다. 특히 Hydreight는 2024년 1분기 30만 9천 달러 손실에서 벗어나 2만 1천 달러의 GAAP 순이익을 달성했으며, 조정 EBITDA는 16만 3천 달러였습니다. 신규 간호사 가입은 65% 증가했고 약국 주문은 48% 성장하는 등 운영 면에서도 큰 성장을 보였습니다. Hydreight는 2월에 540만 달러의 전략적 자금 조달을 완료했으며, VSDHOne 플랫폼에서 개인 맞춤 유전자 검사와 웰니스 솔루션 등 새로운 서비스를 출시했습니다. 회사는 604만 달러의 견고한 현금 보유고를 유지하며 미국 50개 주 전역에 걸쳐 모바일 임상 네트워크를 확장하고 있습니다.
Hydreight Technologies (HYDTF) a annoncé de solides résultats financiers pour le premier trimestre 2025 avec une croissance du chiffre d'affaires de 34 % en glissement annuel. La société a réalisé un chiffre d'affaires total de 6,53 millions de dollars et un chiffre d'affaires GAAP de 4,54 millions de dollars, en hausse par rapport à 3,38 millions de dollars au premier trimestre 2024. Notamment, Hydreight est devenue rentable avec un résultat net GAAP de 21 000 dollars, contre une perte de 309 000 dollars au premier trimestre 2024, et un EBITDA ajusté de 163 000 dollars. L'entreprise a connu une croissance opérationnelle significative avec une augmentation de 65 % des nouvelles inscriptions d'infirmières et une croissance de 48 % des commandes en pharmacie. Hydreight a finalisé un financement stratégique de 5,4 millions de dollars brut en février et a lancé de nouveaux services, notamment des tests génétiques personnalisés et une solution bien-être sur leur plateforme VSDHOne. La société maintient une solide position de trésorerie de 6,04 millions de dollars et continue d'étendre son réseau clinique mobile à travers les 50 États-Unis.
Hydreight Technologies (HYDTF) meldete starke Finanzergebnisse für das erste Quartal 2025 mit einem Umsatzwachstum von 34 % im Jahresvergleich. Das Unternehmen erzielte einen Gesamtumsatz von 6,53 Mio. USD und einen GAAP-Umsatz von 4,54 Mio. USD, gegenüber 3,38 Mio. USD im ersten Quartal 2024. Bemerkenswert ist, dass Hydreight die Profitabilität erreichte mit einem GAAP-Nettoeinkommen von 21.000 USD, verglichen mit einem Verlust von 309.000 USD im ersten Quartal 2024, sowie einem bereinigten EBITDA von 163.000 USD. Das Unternehmen verzeichnete ein erhebliches operatives Wachstum mit einem Anstieg der neuen Krankenschwester-Anmeldungen um 65 % und einem Wachstum der Apothekenbestellungen um 48 %. Hydreight schloss im Februar eine strategische Finanzierung über 5,4 Mio. USD brutto ab und führte neue Dienstleistungen ein, darunter personalisierte Gentests und Wellness-Lösungen auf ihrer VSDHOne-Plattform. Das Unternehmen hält eine starke Liquiditätsposition von 6,04 Mio. USD und erweitert weiterhin sein mobiles klinisches Netzwerk in allen 50 US-Bundesstaaten.
Positive
  • Achieved 34% year-over-year revenue growth to $6.53M in topline revenue
  • Turned profitable with GAAP Net Income of $21K, compared to $309K loss in Q1 2024
  • Secured $5.4M gross ($4.8M net) strategic financing to fuel growth
  • Strong operational metrics with 65% growth in nurse signups and 48% growth in pharmacy orders
  • Healthy cash position of $6.04M at quarter-end
  • Improved gross margin to $1.50M from $1.23M in Q1 2024
Negative
  • Significant gap between topline revenue ($6.53M) and GAAP revenue ($4.54M) due to business partner payouts
  • Continued high investment requirements for first half of 2025 may impact short-term profitability

“It was an outstanding quarter. We exceeded our Q1 projections with approximately 34% YOY growth from our first two verticals, a clear sign that our strategy is working. We also secured new customers for VSDHOne, positioning us strongly to hit our year-end goals with the number of orders. Our continued investments in the first half of 2025 reflect our commitment to scaling efficiently and driving sustainable margin improvements.” – Shane Madden, CEO of Hydreight

VANCOUVER, British Columbia and LAS VEGAS, May 30, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (“Hydreight” or the “Company”) ( TSXV: NURS )( OTCQB: HYDTF )( FSE: SO6 ), a fast-growing mobile clinical network and medical platform which enables flexible at-home medical services across 50 states in the United States, is pleased to announce its financial results for the first quarter ended March 31, 2025. All financial information is presented in Canadian dollars unless otherwise indicated.

Q1 2025 Highlights

  • Topline¹ Revenue of $6.53 million, a 34% year-over-year increase
  • GAAP Revenue of $4.54 million, up from $3.38 million in Q1 2024
  • Gross Margin of $1.50 million, up from $1.23 million in Q1 2024
  • Adjusted EBITDA¹ of $163K, marking continued operational improvement
  • GAAP Net Income of 21K, from GAAP Net Loss of $309K in Q1, 2024
  • Cash on Hand of $6.04 million at quarter-end
  • $5.4M gross ($4.8M net) strategic financing completed in February to fuel growth initiatives
  • Approximately 65% growth in new Nurse signup compared to Q1, 2024
  • Approximately 48% growth in Number of pharmacy orders compared to Q1, 2024
  • Launches Personalized Genetic Testing and Wellness Solution on VSDHOne Platform

Shane Madden, CEO of Hydreight commented, “It was an outstanding quarter. We exceeded our Q1 projections with approximately 34% YOY growth from our first two verticals, a clear sign that our strategy is working. We also secured new customers for VSDHOne, positioning us well to achieve our year-end goals. These accounts are currently onboarding and migrating their new and existing orders to the VSDHOne platform. We’re continuing to increase our investments in the first half of 2025 to support this growth and drive sustainable margin improvements.”

Highlights and Subsequent Events

The Company believes the following Non-GAAP1 financial measures provide meaningful insight to aid in the understanding of the Company’s performance and may assist in the evaluation of the Company’s business relative to that of its peers:

 Three months ended
March 31,
 
 20252024% change
    
Adjusted Revenue$6,527,957 $4,867,004 34%
Deduct - deferred business partner contract revenue 454,140  (116,978) 
Deduct - business partner payouts on app service gross revenue 1,533,695  1,606,376  
GAAP Revenue$4,540,122 $3,377,606 34%
    
Adjusted Gross Margin$1,958,605 $1,114,356 76%
Deduct - deferred business partner contract revenue 454,140  (116,978) 
GAAP Gross Margin$1,504,465 $1,231,334 22%
    
Adjusted EBITDA$163,412 $(45,873)456%
Deduct - amortization and depreciation 101,004  46,553  
Deduct - share-based payments 41,505  216,295  
GAAP Net Income (Loss)$20,903 $(308,721)107%
    

1 Refer to Use of Non-GAAP Financial Measures

The table below sets out a summary of certain financial results of the Company over the past eight quarters and is derived from the audited annual consolidated financial statements and unaudited quarterly interim consolidated financial statements of the Company.

Fiscal Quarter EndedRevenueNet Income (Loss)
After Taxes
 Comprehensive
Income (Loss)
Basic Income
(Loss) Per Share

Diluted Income
(Loss) Per Share

March 31, 20254,540,12220,903 21,652 0.00 0.00 
December 31, 20244,040,57820,577 (106,396)0.00 0.00 
September 30, 20244,526,320(89,938)(53,119)(0.00)(0.00)
June 30, 20244,100,212(27,087)(48,184)(0.00)(0.00)
March 31, 20243,377,606(308,721)(370,559)(0.01)(0.01)
December 31, 20233,373,193(898,561)(865,068)(0.02)(0.02)
September 30, 20233,088,219(466,973)(548,954)(0.01)(0.01)
June 30, 20232,699,668(471,890)(405,638)(0.01)(0.01)
     

Please see SEDAR+ for the Company's condensed consolidated unaudited interim financial statements and MD&A for the three months ended March 31, 2025 and audited annual consolidated financial statements for the year ended December 31, 2024.

The Company has experienced dramatic user growth over the past two years as can be seen by the consistent revenue growth over the past eight quarters. Net loss and comprehensive loss have improved from 2023 and into 2024, with the current quarter reflecting net income.

The Company continues to deliver on its mission of building the largest mobile clinical network in the United States. Through its medical network, pharmacy network and proprietary technology platform that adheres to the complex healthcare legislation across 50 states, Hydreight has provided a fully integrated solution for healthcare providers to become independent contractors.

Strategic Outlook

Hydreight remains focused on scaling responsibly while improving margins and capturing market share in the high-growth digital health space. Key priorities for the remainder of 2025 include:

  1. Focusing on Growth and our projections across three verticals
  2. Achieving profitability and sustaining positive Adjusted EBITDA
  3. Expanding offerings across genetic testing, anti-aging, and mental wellness
  4. Driving onboarding of high-volume franchise and D2C partners
  5. Pursuing strategic tuck-in M&A opportunities and investment that helps with our revenue and/or margins

On behalf of the Board of Directors
Shane Madden
Director and Chief Executive Officer
Hydreight Technologies Inc.

Contact
Email: ir@hydreight.com; Telephone: (702) 970-8112

Hydreight Technologies Inc Ranked Number 56 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

Hydreight Technologies Recognized as a Top 50 TSX Venture Exchange Company

This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.

About Hydreight Technologies Inc.

Hydreight Technologies Inc is building one of the largest mobile clinic networks in the United States. Its proprietary, fully integrated platform has hosted a network of over 3000 nurses, over 200 doctors and a pharmacy network through its Doctor networks across 50 states. The platform includes a built-in, easy-to-use suite of fully integrated tools for accounting, documentation, sales, inventory, booking, and managing patient data, which enables licensed healthcare professionals to provide services directly to patients at home, office or hotel. Hydreight is bridging the gap between provider compliance and patient convenience, empowering nurses, med spa technicians, and other licensed healthcare professionals. The Hydreight platform allows healthcare professionals to deliver services independently, on their own terms, or to add mobile services to existing location-based operations. Hydreight has a 503B pharmacy network servicing all 50 states and is closely affiliated with a U.S. certified e-script and telemedicine provider network.

About VSDHOne - Direct to Consumer Platform

Developed in partnership with Victory Square Technologies, Hydreight Technologies launched the VSDHOne (Read as VSDH-One) platform. VSDHOne simplifies the entry challenges for companies and medi-spa businesses to enter the online healthcare space compliantly. This platform will help all businesses to launch a direct-to-consumer healthcare brand in a matter of days in all 50 states. Compliant offerings include: GLP-1s, peptides, personalized healthcare treatments, sermorelin, testosterone replacement therapy (“TRT”), hair loss, skincare, sexual health and more. Hydreight invested in technology, legal and infrastructure to launch this platform. The VSDHOne platform offers a complete, end-to-end solution for businesses looking to launch direct-to-consumer healthcare brands. From compliance and telemedicine technology to nationwide doctor and pharmacy networks, VSDHOne provides all the tools needed for a seamless entry into the online healthcare space. The platform is designed to significantly reduce the time and costs associated with launching such services, making it possible for businesses to go live in days instead of months.

Neither TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.

Use of Non-GAAP Financial Measures:

This release contains references to non-GAAP financial measures Adjusted Revenue, Adjusted Gross Margin and Adjusted EBITDA. The Company defines Adjusted Revenue as gross cash income before adjustment for the deferred portion of business partner contract revenue and gross receipts from Hydreight App service sales. The Company defines Adjusted Gross Margin as GAAP gross margin plus inventory impairment plus the deferred portion of business partner contract revenue. The Company defines Adjusted EBITDA as net income (loss) before interest, taxes, depreciation and amortization and before (i) transaction, restructuring, and integration costs and share-based payments expense, and (iii) gains/losses that are not reflective of ongoing operating performance. The Company believes that the measures provide information useful to its shareholders and investors in understanding the Company’s operating cash flow growth, user growth, and cash generating potential and may assist in the evaluation of the Company’s business relative to that of its peers more accurately than GAAP financial measures alone. This data is furnished to provide additional information and does not have any standardized meaning prescribed by GAAP. Accordingly, it should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP and is not necessarily indicative of other metrics presented in accordance with GAAP.

Neither TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.

Cautionary Note Regarding Forward-Looking Information

This press release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes information regarding expectations for the 2025 strategic outlook, Company's growth, Margins and VSDHOne’s and Hydreight’s growth and numbers in 2025.

Investors are cautioned that forward-looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the ability to obtain requisite regulatory and other approvals with respect to the business operated by the Company and/or the potential impact of the listing of the Company’s shares on the TSXV on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation; and the diversion of management time as a result of being a publicly listed entity. This forward-looking information may be affected by risks and uncertainties in the business of the Company and market conditions.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

1 See Use of Non-GAAP Financial Measures


FAQ

What was Hydreight's (HYDTF) revenue growth in Q1 2025?

Hydreight reported a 34% year-over-year revenue growth, with topline revenue of $6.53 million and GAAP revenue of $4.54 million in Q1 2025.

Did Hydreight (HYDTF) achieve profitability in Q1 2025?

Yes, Hydreight achieved profitability with GAAP Net Income of $21,000, compared to a loss of $309,000 in Q1 2024, and Adjusted EBITDA of $163,000.

How much cash does Hydreight (HYDTF) have on hand after Q1 2025?

Hydreight reported $6.04 million in cash on hand at the end of Q1 2025, bolstered by a $5.4M gross strategic financing completed in February.

What was Hydreight's (HYDTF) operational growth in Q1 2025?

Hydreight saw 65% growth in new nurse signups and 48% growth in pharmacy orders compared to Q1 2024.

What new services did Hydreight (HYDTF) launch in Q1 2025?

Hydreight launched Personalized Genetic Testing and Wellness Solution on their VSDHOne Platform, along with new offerings in GLP-1 telehealth and NAD+ therapy.
Hydreight Tech

OTC:HYDTF

HYDTF Rankings

HYDTF Latest News

HYDTF Stock Data

33.66M
18.40M
64.75%
Health Information Services
Healthcare
Link
United States
Las Vegas